Losartan Attenuates Degradation of Aorta and Lung Tissue Micromechanics in a Mouse Model of Severe Marfan Syndrome

[1]  J. Humphrey,et al.  Differential ascending and descending aortic mechanics parallel aneurysmal propensity in a mouse model of Marfan syndrome. , 2016, Journal of biomechanics.

[2]  Ramon Farré,et al.  Early Impairment of Lung Mechanics in a Murine Model of Marfan Syndrome , 2016, PloS one.

[3]  B. Wentworth,et al.  Dimorphic Effects of Transforming Growth Factor-&bgr; Signaling During Aortic Aneurysm Progression in Mice Suggest a Combinatorial Therapy for Marfan Syndrome , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[4]  J. Elefteriades,et al.  Atenolol versus Losartan in Marfan's Syndrome. , 2015, The New England journal of medicine.

[5]  J. Pepper,et al.  Atenolol versus Losartan in Marfan's Syndrome. , 2015, The New England journal of medicine.

[6]  Jeffrey A. Jones,et al.  Relation of Murine Thoracic Aortic Structural and Cellular Changes With Aging to Passive and Active Mechanical Properties , 2015, Journal of the American Heart Association.

[7]  A. Dore,et al.  The ascending aortic aneurysm: When to intervene? , 2015, International journal of cardiology. Heart & vasculature.

[8]  L. Ge,et al.  Patient-specific finite element analysis of ascending thoracic aortic aneurysm. , 2014, The Journal of heart valve disease.

[9]  Sarah J. Parker,et al.  Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. , 2014, The Journal of clinical investigation.

[10]  T Christian Gasser,et al.  Importance of material model in wall stress prediction in abdominal aortic aneurysms. , 2013, Medical engineering & physics.

[11]  Santanu Chandra,et al.  The Role of Geometric and Biomechanical Factors in Abdominal Aortic Aneurysm Rupture Risk Assessment , 2013, Annals of Biomedical Engineering.

[12]  D. Iliopoulos,et al.  Effect of layer heterogeneity on the biomechanical properties of ascending thoracic aortic aneurysms , 2012, Medical & Biological Engineering & Computing.

[13]  B. Baxter,et al.  MMP-2 Regulates Erk1/2 Phosphorylation and Aortic Dilatation in Marfan Syndrome , 2012, Circulation research.

[14]  J. Beenakker,et al.  Mechanical properties of the extracellular matrix of the aorta studied by enzymatic treatments. , 2012, Biophysical journal.

[15]  Jay D Humphrey,et al.  Mechanical assessment of elastin integrity in fibrillin-1-deficient carotid arteries: implications for Marfan syndrome. , 2011, Cardiovascular research.

[16]  B. Mulder,et al.  Age‐related and regional changes of aortic stiffness in the marfan syndrome: Assessment with velocity‐encoded MRI , 2011, Journal of magnetic resonance imaging : JMRI.

[17]  D. Quaglino,et al.  Fibrillin‐1 genetic deficiency leads to pathological ageing of arteries in mice , 2011, The Journal of pathology.

[18]  M. Burnier,et al.  Pharmacokinetic evaluation of losartan , 2011, Expert opinion on drug metabolism & toxicology.

[19]  Cynthia A. Reinhart-King,et al.  Indentation measurements of the subendothelial matrix in bovine carotid arteries. , 2011, Journal of biomechanics.

[20]  H. Dietz,et al.  Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. , 2010, Human molecular genetics.

[21]  Elliot L Elson,et al.  Short Communication: Vascular Smooth Muscle Cell Stiffness As a Mechanism for Increased Aortic Stiffness With Aging , 2010, Circulation research.

[22]  R. Bank,et al.  Distinct defects in collagen microarchitecture underlie vessel-wall failure in advanced abdominal aneurysms and aneurysms in Marfan syndrome , 2009, Proceedings of the National Academy of Sciences.

[23]  K. Costa,et al.  Developing a hybrid computational model of AFM indentation for analysis of mechanically heterogeneous samples , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[24]  C. van Breemen,et al.  Dysfunction of endothelial and smooth muscle cells in small arteries of a mouse model of Marfan syndrome , 2009, British journal of pharmacology.

[25]  C. van Breemen,et al.  Long‐term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome , 2009, British journal of pharmacology.

[26]  D. Rifkin,et al.  Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling. , 2009, Current opinion in cell biology.

[27]  J. D. Humphrey,et al.  Mechanics of Carotid Arteries in a Mouse Model of Marfan Syndrome , 2009, Annals of Biomedical Engineering.

[28]  D. Milewicz,et al.  Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders. , 2008, Circulation.

[29]  Gerard A Ateshian,et al.  Heterogeneous transmural proteoglycan distribution provides a mechanism for regulating residual stresses in the aorta. , 2008, American journal of physiology. Heart and circulatory physiology.

[30]  D. Judge,et al.  Loss of Elastic Fiber Integrity and Reduction of Vascular Smooth Muscle Contraction Resulting From the Upregulated Activities of Matrix Metalloproteinase-2 and -9 in the Thoracic Aortic Aneurysm in Marfan Syndrome , 2007, Circulation research.

[31]  D. Judge,et al.  Endothelial dysfunction and compromised eNOS/Akt signaling in the thoracic aorta during the progression of Marfan syndrome , 2007, British journal of pharmacology.

[32]  D. Judge,et al.  Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.

[33]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[34]  A. Vitarelli,et al.  Aortic wall mechanics in the Marfan syndrome assessed by transesophageal tissue Doppler echocardiography. , 2006, The American journal of cardiology.

[35]  R. Sauer,et al.  A circular inclusion in a finite domain I. The Dirichlet-Eshelby problem , 2005 .

[36]  D. Milewicz,et al.  Treatment of aortic disease in patients with Marfan syndrome. , 2005, Circulation.

[37]  K. Lutchen,et al.  Mechanics, nonlinearity, and failure strength of lung tissue in a mouse model of emphysema: possible role of collagen remodeling. , 2005, Journal of applied physiology.

[38]  Jessica Geubtner,et al.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. , 2004, The Journal of clinical investigation.

[39]  M. Toshima,et al.  Three-dimensional architecture of elastin and collagen fiber networks in the human and rat lung. , 2004, Archives of histology and cytology.

[40]  C. Speer,et al.  Impact of Basic Research on Tomorrow's MedicineThe Role of Transforming Growth Factor β in Lung Development and Disease , 2004 .

[41]  Arnab Majumdar,et al.  Lung and alveolar wall elastic and hysteretic behavior in rats: effects of in vivo elastase treatment. , 2003, Journal of applied physiology.

[42]  V. Kaartinen,et al.  Fibrillin controls TGF-β activation , 2003, Nature Genetics.

[43]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[44]  Thoralf M. Sundt,et al.  Mechanical Properties of Dilated Human Ascending Aorta , 2002, Annals of Biomedical Engineering.

[45]  ValérieMarque,et al.  Aortic Wall Mechanics and Composition in a Transgenic Mouse Model of Marfan Syndrome , 2001 .

[46]  H. Dietz,et al.  Phenotypic Alteration of Vascular Smooth Muscle Cells Precedes Elastolysis in a Mouse Model of Marfan Syndrome , 2001, Circulation research.

[47]  N. Arakawa,et al.  Peripheral resistance vessel dysfunction in Marfan syndrome. , 2000, American heart journal.

[48]  K. Costa,et al.  Analysis of indentation: implications for measuring mechanical properties with atomic force microscopy. , 1999, Journal of biomechanical engineering.

[49]  E E van der Wall,et al.  The influence of aging and aortic stiffness on permanent dilation and breaking stress of the thoracic descending aorta. , 1999, Cardiovascular research.

[50]  H. Dietz,et al.  Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A de Roos,et al.  Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. , 1998, The American journal of cardiology.

[52]  J. Crapo,et al.  Spatial distribution of collagen and elastin fibers in the lungs. , 1990, Journal of applied physiology.

[53]  A. Child,et al.  Pulmonary disease in patients with Marfan syndrome. , 1984, Thorax.

[54]  C. E. Perlman,et al.  Micromechanics of alveolar edema. , 2011, American journal of respiratory cell and molecular biology.

[55]  J. Stockman,et al.  Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome , 2010 .

[56]  T. Graham.  Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome , 2009 .

[57]  Jay D Humphrey,et al.  Biaxial biomechanical adaptations of mouse carotid arteries cultured at altered axial extension. , 2007, Journal of biomechanics.

[58]  C. Speer,et al.  The role of transforming growth factor beta in lung development and disease. , 2004, Chest.

[59]  D. Arking,et al.  Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. , 2003, Nature genetics.

[60]  V. Kaartinen,et al.  Fibrillin controls TGF-beta activation. , 2003, Nature genetics.